Prospective Validation of HLA-DRB1*07:01 Allele Carriage As a Predictive Risk Factor for Lapatinib-Induced Liver Injury
Authors:
- Daniel J. SchaidDSDaniel J. Schaid
- Colin F. SpraggsCSColin F. Spraggs
- Shannon K. McDonnellSMShannon K. McDonnell
- Laura R. ParhamLPLaura R. Parham
- Charles J. CoxCCCharles J. Cox
- Bent EjlertsenBEBent Ejlertsen
- Dianne M. FinkelsteinDFDianne M. Finkelstein
- Erica RappoldERErica Rappold
- Joan CurranJCJoan Curran
- Lon R. CardonLCLon R. Cardon
- Paul E. GossPGPaul E. Goss
- 1 August 2014
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (22) , 2296-2303
Abstract
Purpose: Liver injury is a serious adverse event leading to permanent discontinuation of lapatinib in affected patients. This study aimed to validate previously associated major histocompatibility complex (MHC) variants as predictors of risk of liver injury by using a large, randomized, placebo-controlled trial of lapatinib in human epidermal growth factor receptor 2–positive, early-stage breast cancer (Tykerb Evaluation After Chemotherapy [TEACH]: Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer). Patients and Methods: The frequency of ALT elevation cases was compared among four MHC variants in 1,194 patients randomly assigned to lapatinib. Cumulative ALT elevation time courses during treatment were also compared between carriers and noncarriers of specified MHC variants. Results: In lapatinib-treated patients, there was a significant difference in ALT case incidence between HLA carriers and noncarriers. The highly correlated alleles HLA-DRB1*07:01 and HLA-DQA1*02:01 (study frequency, 22.4%) were associated with ALT elevation (odds ratio, 14) between cases (n = 37) and controls (n = 1,071). These associations strengthened at higher ALT elevation thresholds and in Hy's Law cases. In lapatinib-treated patients, the overall risk for National Cancer Institute-Common Terminology Criteria for Adverse Events grade 3 ALT elevation (> 5× upper limit of normal) was 2.1%; HLA allele carriers had an increased risk of 7.7%; in noncarriers, risk was reduced to 0.5%, comparable to ALT elevation for all patients receiving placebo. The increase in ALT case incidence in the lapatinib arm showed no evidence of plateau during 1 year of lapatinib treatment. Conclusion: These results validate HLA-DRB1*07:01 allele carriage as a predictor of increased risk of lapatinib-induced liver injury and implicate an immune pathology. The HLA association could support clinical management of patients experiencing hepatotoxicity during lapatinib treatment.Keywords
This publication has 17 references indexed in Scilit:
- Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registryHuman Immunology, 2013
- Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in TaiwanNew England Journal of Medicine, 2011
- HLA-DQA1*02:01 Is a Major Risk Factor for Lapatinib-Induced Hepatotoxicity in Women With Advanced Breast CancerJournal of Clinical Oncology, 2011
- Pharmacogenetics of Drug HypersensitivityPharmacogenomics, 2010
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical ChallengesJournal of Clinical Oncology, 2009
- Reply to W.F. Pirl et alJournal of Clinical Oncology, 2009
- HLA-B*5701 Screening for Hypersensitivity to AbacavirNew England Journal of Medicine, 2008
- MHC class II proteins and disease: a structural perspectiveNature Reviews Immunology, 2006
- Population Structure and EigenanalysisPLOS Genetics, 2006